Beijing Puqi Pharmaceutical Technology Co Ltd.

Main objectives (1) To quantitatively analyze the total radioactivity in the excreta after intravenous administration of [14C]PG-011 in healthy male subjects, and to obtain the recovery rate of radioactivity in humans and the main excretion pathway; (2) To investigate the distribution ratio of total radioactivity in whole blood and plasma after intravenous administration of [14C]PG-011 in healthy male subjects, as well as the pharmacokinetic characteristics of total radioactivity in whole blood (if applicable) and plasma; (3) To obtain the radioactive metabolite profiles in plasma, urine, and feces of healthy male subjects after intravenous administration of [14C]PG-011, to identify the main metabolites, and to determine the main biotransformation pathways. Secondary objectives: (1) To quantitatively analyze the concentrations of [14C]PG-011 (if applicable), PG-011 and its major metabolites (if applicable) in plasma, obtain the pharmacokinetic parameters of [14C]PG-011 (if applicable), PG-011 and its major metabolites (if applicable) in plasma, and obtain the absolute bioavailability (F) of PG-011 after nasal spray administration; (2) To observe the safety of PG-011 after nasal spray administration and intravenous administration in healthy Chinese adult male subjects.